Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 40 results for bph

  1. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    Evidence-based recommendations on GreenLight XPS for benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    29 November 2022
    View recommendations

    Sections for MTG74

  2. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    24 June 2020
    View recommendations

    Sections for MTG49

  3. Northampton General Day Case BPH service evaluation – adoption of Urolift

    patients as alternative to TURP for troublesome symptoms of Benign Prostate Hyperplasia (BPH) would result in cost and...

    Shared learning
    Published
    17 January 2020

  4. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia

    Awaiting development [GID-MT599] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  5. Insights from the NHS: adoption of UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia at St Helens and Knowsley Teaching Hospital NHS Trust

    that can happen as a result of treatment for benign prostatic hyperplasia (BPH), the Urology team at the trust were interested in the...

    Shared learning
    Last updated
    27 January 2017

  6. Adoption of UroLift procedure, an ambulatory pathway for patients suffering from Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia

    November 2016 Benign Prostate Hyperplasia (BPH) is a long-term and progressive condition, resulting in lower

    Shared learning
    Last updated
    12 September 2019

  7. Echolaser for BPH

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  8. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB315)

    NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    31 January 2023

  9. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG770)

    Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.

    Interventional procedures guidance
    Published
    14 September 2023
    View recommendations

    Sections for IPG770

  10. Urolift – a community-based alternative treatment for Benign Prostatic Obstruction (BPO)

    lower urinary tract symptoms of benign prostatic hyperplasia. BPO describes the cause of lower urinary tract symptoms from...

    Shared learning
    Last updated
    10 March 2020

  11. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

    NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...

    Technology appraisal guidance
    Published
    23 January 2013

    Sections for TA273

  12. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    4 May 2021
    View recommendations

    Sections for MTG58

  13. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

    Clinical guideline
    Last updated
    3 June 2015
    View recommendations

    Sections for CG97

  14. Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

    NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .

    Medtech innovation briefing
    Published
    2 October 2017

  15. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    21 September 2022